Mr. Harry Pollack
President and CEO
National Chemical Laboratories
401 N. 10th Street
Philadelphia , PA 19123-3803
United StatesFEI 1000071237Issued Nov 8, 2023Office of Pharmaceutical Quality Operations
Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy. To check it, open FDA's record for this establishment, listed under FEI 1000071237.
Violations3
Issue DateNov 8, 2023
Product TypeDrugs
StatusOpen
Letter Details
Firm
National Chemical Laboratories
Location
Mr. Harry Pollack
President and CEO
National Chemical Laboratories
401 N. 10th Street
Philadelphia , PA 19123-3803
United States
FEI Number
1000071237
Country
United States
Issue Date
November 08, 2023
Issuing Office
Office of Pharmaceutical Quality Operations
Product Type
Drugs
Status
Open
Summary
National Chemical Laboratories, a pharmaceutical manufacturer of OTC topical drugs including benzalkonium chloride-based hand sanitizers, violated Current Good Manufacturing Practice (CGMP) regulations during an FDA inspection in May 2023. The company failed to validate and establish the reliability of component suppliers' test analyses at appropriate intervals, relying instead on supplier certificates of analysis without conducting independent testing to verify that benzalkonium chloride and other components conformed to specifications. This failure to adequately test components meant the firm lacked scientific evidence that materials were suitable for use in drug manufacturing, rendering their finished products adulterated. The company's corrective action plan to establish a supplier qualification program and conduct retrospective testing of affected lots was deemed inadequate by the FDA.
National Chemical Laboratories FDA Warning Letter, November 8, 2023